Latest Chembio Diagnostics (CEMI) Headlines C
Post# of 40
Posted On: 03/09/2014 6:56:31 AM
Latest Chembio Diagnostics (CEMI) Headlines
Chembio Diagnostics announces record 2013 revenues of USD29.55m and tenth consecutive year of double-digit organic revenue growth
M2 - Fri Mar 07, 4:41AM CST
Diagnostic tests company Chembio Diagnostics (NasdaqCM:CEMI) stated on Thursday that its net income was USD531,000 (USD0.06 per diluted share) for year ended 31 December 2013.
Chembio Diagnostics Reports 2013 Financial Results
GlobeNewswire - Thu Mar 06, 8:24AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious diseases, today reported financial results for the quarter and year ended December 31, 2013, which include record revenues, and a tenth consecutive year of double-digit organic revenue growth.
Chembio Diagnostics, Inc. to Host Fourth Quarter Earnings Webcast Live on Thursday, March 6, 2014
ACCESSWIRE - Wed Mar 05, 8:35AM CST
MEDFORD, NY / ACCESSWIRE / March 5, 2014 / Chembio Diagnostics, Inc. (CEMI) will host a live webcast to discuss the results of the fourth quarter 2013, to be held Thursday, March 6, 2014 at 10:00 AM Eastern Time.
Chembio to Host Conference Call to Discuss 2013 Financial Results
GlobeNewswire - Thu Feb 20, 7:50AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), which develops, manufactures, markets and licenses point-of-care diagnostic tests, announced today that the Company will release financial results for the year of 2013, before the open of the market on Thursday, March 6, 2014. The Company's 10-K and earnings press release will be available by 9:00 a.m. on our web site.
Chembio Diagnostics Inc & RVR Diagnostics enters into agreements in Southeast Asia, with access to new markets for the patented DPP technology
M2 - Thu Feb 13, 6:12AM CST
Diagnostic tests company Chembio Diagnostics Inc (NasdaqCM:CEMI) said on Wednesday that it has signed a license as well as a manufacturing agreement for its patented DPP technology with RVR Diagnostics SDN BHD based in Malaysia.
Chembio Enters Agreements With RVR in Southeast Asia
GlobeNewswire - Wed Feb 12, 7:50AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care ("POC") diagnostic tests for infectious diseases, announced today that it has entered into two agreements with RVR Diagnostics SDN BHD ("RVR"), a privately-held company in Malaysia. The agreements support Chembio's strategy of establishing a market presence in Asia, in collaboration with RVR as a licensee, distributor, and contract manufacturer. The agreements grant exclusive distribution rights to RVR in certain countries in the region and enable RVR to manufacture Chembio's DPP(R) HIV 1/2 Assay and DPP(R) HIV-Syphilis Assay and potentially other products developed by Chembio incorporating its patented DPP(R) technology.
Chembio Provides Update on DPP(R) HIV 1/2 Assay CLIA Waiver Application
GlobeNewswire - Mon Feb 10, 7:50AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI) a leader in point-of-care diagnostic tests for infectious diseases, today provided an update on its discussions with the U.S. Food and Drug Administration (FDA) concerning the company's CLIA waiver application for its DPP(R) HIV 1/2 Assay. The DPP(R) HIV 1/2 Assay was approved by the FDA for professional use under an approved Pre-Marketing Application in December 2012. During 2013 untrained user studies were performed in support of a CLIA waiver application which was filed with the FDA at the end of November. During a recent discussion, the FDA indicated that additional new infections should be detected to strengthen Chembio's data that the DPP HIV 1/2 Assay performs equivalently in the hands of the untrained user as compared to the professional user. Chembio is currently working with the FDA to define the specific additional requirements necessary for satisfactory completion of the CLIA waiver application.
Chembio Diagnostics to Present at Three Conferences in January 2014
GlobeNewswire - Thu Jan 09, 2:15PM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI) a leader in point-of-care ("POC") diagnostic tests for infectious diseases, announced today that Lawrence A. Siebert, Chief Executive Officer, will present at three investor conferences next week. These presentations will provide an overview of the company's products and programs as well as anticipated milestones for 2014. Details regarding these events are as follows:
Chembio to Present at the LD Micro VI: The Main Event Conference
GlobeNewswire - Tue Dec 03, 7:50AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, announces that Lawrence A. Siebert, Chief Executive Officer, will present at the LD Micro VI: The Main Event Conference to be held December 3 - 5, 2013 in Los Angeles, CA. Mr. Siebert will be presenting at 10:00 am (PT) on Thursday, December 5, Track Four. One-on-one meetings with investors will be held during the conference to discuss the Company's strategy for continued growth. To schedule a meeting with Chembio management, please call conference organizers at 408-457-1042. Attendance at the conference is by invitation only.
Chembio Files for CLIA Waiver with FDA for Point-of-Care DPP(R) HIV 1/2 Assay
GlobeNewswire - Mon Dec 02, 7:50AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care ("POC") diagnostic tests for infectious diseases, has completed its Clinical Laboratory Improvement Amendment ("CLIA") waiver studies for its DPP(R) HIV 1/2 Assay (the "Assay"). The Company believes the study results meet CLIA waiver requirements and it has filed the CLIA waiver application with the U.S. Food and Drug Administration ("FDA").
Chembio Board Member Named Winner of Commercialization Award by Purdue University
GlobeNewswire - Thu Nov 21, 1:00PM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI) a leader in point-of-care ("POC") diagnostic tests for infectious diseases, announced today that Peter Kissinger, Ph.D., a member of the company's board of directors and professor of chemistry at Purdue University, has received the Outstanding Commercialization Award for Purdue University for 2013. The award is given annually to a Purdue University faculty member in recognition of outstanding contributions to, and success with, commercializing the University's research discoveries.
Chembio Diagnostics Reports Third Quarter 2013 Financial Results
GlobeNewswire - Thu Nov 07, 3:08PM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious diseases, today reported financial results for the three and nine months ended September 30, 2013.
Chembio Diagnostics, Inc. to Host Third Quarter 2013 Earnings Webcast Live on Thursday, November 7, 2013
ACCESSWIRE - Wed Nov 06, 8:34AM CST
MEDFORD, NY - (ACCESSWIRE - November 6, 2013) - Chembio Diagnostics, Inc. (CEMI) will host a live webcast to discuss the results of the third quarter 2013, to be held Thursday, November 7, 2013 at 4:30 p.m. Eastern Time. Presenters for the event will include Lawrence A. Siebert, President and Chief Executive Officer and Richard Larkin, Chief Financial Officer.
Chembio Launches DPP(R) HIV-Syphilis Test
GlobeNewswire - Thu Oct 31, 8:00AM CDT
Receives First Purchase Order from Mexican Distributor
Chembio to Host Conference Call to Discuss Third Quarter 2013 Financial Results
GlobeNewswire - Thu Oct 24, 7:50AM CDT
Chembio Diagnostics, Inc. (Nasdaq:CEMI), which develops, manufactures, markets and licenses point-of-care diagnostic tests, announced today that the Company will release financial results for the third quarter of 2013, after the close of the market on Thursday, November 7, 2013. The Company's 10-Q and earnings press release will be available immediately after 4:00 p.m. on our web site.
OTC Daily Alert Stock Watch - Chembio Diagnostics, Inc.,. (NASDAQ: CEMI)
WorldStockWire - Wed Sep 11, 9:00PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Chembio Diagnostics Inc announces planned retirement of Lawrence A. Siebert as CEO & president on 11 May 2014
M2 - Fri Sep 06, 5:27AM CDT
Diagnostic tests company Chembio Diagnostics Inc (NasdaqCM:CEMI) said on Thursday that Lawrence A. Siebert plans to step down as its chief executive officer and president with the expiry of his employment agreement on 11 May 2014.
Chembio CEO Announces Retirement for May 2014
GlobeNewswire - Thu Sep 05, 7:50AM CDT
Chembio Diagnostics, Inc.(Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious diseases, today announced that Lawrence A. Siebert has stated his intention to retire from his positions as chief executive officer and president of the company and its wholly-owned subsidiary when his current employment agreement expires May 11, 2014. The board of directors is now commencing a search for a new CEO.
Chembio Diagnostics Reports Second Quarter 2013 Financial Results
GlobeNewswire - Thu Aug 08, 7:50AM CDT
Chembio Diagnostics, Inc.(Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious diseases, today reported financial results for the three months and six months ended June 30, 2013.
Alere Beats, Earnings Up 40.5% - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 07, 11:15AM CDT
Net revenues went up 9.1% to $764.0 million in the second quarter of 2013, exceeding the Zacks Consensus Estimate of $722 million
Chembio Diagnostics announces record 2013 revenues of USD29.55m and tenth consecutive year of double-digit organic revenue growth
M2 - Fri Mar 07, 4:41AM CST
Diagnostic tests company Chembio Diagnostics (NasdaqCM:CEMI) stated on Thursday that its net income was USD531,000 (USD0.06 per diluted share) for year ended 31 December 2013.
Chembio Diagnostics Reports 2013 Financial Results
GlobeNewswire - Thu Mar 06, 8:24AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious diseases, today reported financial results for the quarter and year ended December 31, 2013, which include record revenues, and a tenth consecutive year of double-digit organic revenue growth.
Chembio Diagnostics, Inc. to Host Fourth Quarter Earnings Webcast Live on Thursday, March 6, 2014
ACCESSWIRE - Wed Mar 05, 8:35AM CST
MEDFORD, NY / ACCESSWIRE / March 5, 2014 / Chembio Diagnostics, Inc. (CEMI) will host a live webcast to discuss the results of the fourth quarter 2013, to be held Thursday, March 6, 2014 at 10:00 AM Eastern Time.
Chembio to Host Conference Call to Discuss 2013 Financial Results
GlobeNewswire - Thu Feb 20, 7:50AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), which develops, manufactures, markets and licenses point-of-care diagnostic tests, announced today that the Company will release financial results for the year of 2013, before the open of the market on Thursday, March 6, 2014. The Company's 10-K and earnings press release will be available by 9:00 a.m. on our web site.
Chembio Diagnostics Inc & RVR Diagnostics enters into agreements in Southeast Asia, with access to new markets for the patented DPP technology
M2 - Thu Feb 13, 6:12AM CST
Diagnostic tests company Chembio Diagnostics Inc (NasdaqCM:CEMI) said on Wednesday that it has signed a license as well as a manufacturing agreement for its patented DPP technology with RVR Diagnostics SDN BHD based in Malaysia.
Chembio Enters Agreements With RVR in Southeast Asia
GlobeNewswire - Wed Feb 12, 7:50AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care ("POC") diagnostic tests for infectious diseases, announced today that it has entered into two agreements with RVR Diagnostics SDN BHD ("RVR"), a privately-held company in Malaysia. The agreements support Chembio's strategy of establishing a market presence in Asia, in collaboration with RVR as a licensee, distributor, and contract manufacturer. The agreements grant exclusive distribution rights to RVR in certain countries in the region and enable RVR to manufacture Chembio's DPP(R) HIV 1/2 Assay and DPP(R) HIV-Syphilis Assay and potentially other products developed by Chembio incorporating its patented DPP(R) technology.
Chembio Provides Update on DPP(R) HIV 1/2 Assay CLIA Waiver Application
GlobeNewswire - Mon Feb 10, 7:50AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI) a leader in point-of-care diagnostic tests for infectious diseases, today provided an update on its discussions with the U.S. Food and Drug Administration (FDA) concerning the company's CLIA waiver application for its DPP(R) HIV 1/2 Assay. The DPP(R) HIV 1/2 Assay was approved by the FDA for professional use under an approved Pre-Marketing Application in December 2012. During 2013 untrained user studies were performed in support of a CLIA waiver application which was filed with the FDA at the end of November. During a recent discussion, the FDA indicated that additional new infections should be detected to strengthen Chembio's data that the DPP HIV 1/2 Assay performs equivalently in the hands of the untrained user as compared to the professional user. Chembio is currently working with the FDA to define the specific additional requirements necessary for satisfactory completion of the CLIA waiver application.
Chembio Diagnostics to Present at Three Conferences in January 2014
GlobeNewswire - Thu Jan 09, 2:15PM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI) a leader in point-of-care ("POC") diagnostic tests for infectious diseases, announced today that Lawrence A. Siebert, Chief Executive Officer, will present at three investor conferences next week. These presentations will provide an overview of the company's products and programs as well as anticipated milestones for 2014. Details regarding these events are as follows:
Chembio to Present at the LD Micro VI: The Main Event Conference
GlobeNewswire - Tue Dec 03, 7:50AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, announces that Lawrence A. Siebert, Chief Executive Officer, will present at the LD Micro VI: The Main Event Conference to be held December 3 - 5, 2013 in Los Angeles, CA. Mr. Siebert will be presenting at 10:00 am (PT) on Thursday, December 5, Track Four. One-on-one meetings with investors will be held during the conference to discuss the Company's strategy for continued growth. To schedule a meeting with Chembio management, please call conference organizers at 408-457-1042. Attendance at the conference is by invitation only.
Chembio Files for CLIA Waiver with FDA for Point-of-Care DPP(R) HIV 1/2 Assay
GlobeNewswire - Mon Dec 02, 7:50AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care ("POC") diagnostic tests for infectious diseases, has completed its Clinical Laboratory Improvement Amendment ("CLIA") waiver studies for its DPP(R) HIV 1/2 Assay (the "Assay"). The Company believes the study results meet CLIA waiver requirements and it has filed the CLIA waiver application with the U.S. Food and Drug Administration ("FDA").
Chembio Board Member Named Winner of Commercialization Award by Purdue University
GlobeNewswire - Thu Nov 21, 1:00PM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI) a leader in point-of-care ("POC") diagnostic tests for infectious diseases, announced today that Peter Kissinger, Ph.D., a member of the company's board of directors and professor of chemistry at Purdue University, has received the Outstanding Commercialization Award for Purdue University for 2013. The award is given annually to a Purdue University faculty member in recognition of outstanding contributions to, and success with, commercializing the University's research discoveries.
Chembio Diagnostics Reports Third Quarter 2013 Financial Results
GlobeNewswire - Thu Nov 07, 3:08PM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious diseases, today reported financial results for the three and nine months ended September 30, 2013.
Chembio Diagnostics, Inc. to Host Third Quarter 2013 Earnings Webcast Live on Thursday, November 7, 2013
ACCESSWIRE - Wed Nov 06, 8:34AM CST
MEDFORD, NY - (ACCESSWIRE - November 6, 2013) - Chembio Diagnostics, Inc. (CEMI) will host a live webcast to discuss the results of the third quarter 2013, to be held Thursday, November 7, 2013 at 4:30 p.m. Eastern Time. Presenters for the event will include Lawrence A. Siebert, President and Chief Executive Officer and Richard Larkin, Chief Financial Officer.
Chembio Launches DPP(R) HIV-Syphilis Test
GlobeNewswire - Thu Oct 31, 8:00AM CDT
Receives First Purchase Order from Mexican Distributor
Chembio to Host Conference Call to Discuss Third Quarter 2013 Financial Results
GlobeNewswire - Thu Oct 24, 7:50AM CDT
Chembio Diagnostics, Inc. (Nasdaq:CEMI), which develops, manufactures, markets and licenses point-of-care diagnostic tests, announced today that the Company will release financial results for the third quarter of 2013, after the close of the market on Thursday, November 7, 2013. The Company's 10-Q and earnings press release will be available immediately after 4:00 p.m. on our web site.
OTC Daily Alert Stock Watch - Chembio Diagnostics, Inc.,. (NASDAQ: CEMI)
WorldStockWire - Wed Sep 11, 9:00PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Chembio Diagnostics Inc announces planned retirement of Lawrence A. Siebert as CEO & president on 11 May 2014
M2 - Fri Sep 06, 5:27AM CDT
Diagnostic tests company Chembio Diagnostics Inc (NasdaqCM:CEMI) said on Thursday that Lawrence A. Siebert plans to step down as its chief executive officer and president with the expiry of his employment agreement on 11 May 2014.
Chembio CEO Announces Retirement for May 2014
GlobeNewswire - Thu Sep 05, 7:50AM CDT
Chembio Diagnostics, Inc.(Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious diseases, today announced that Lawrence A. Siebert has stated his intention to retire from his positions as chief executive officer and president of the company and its wholly-owned subsidiary when his current employment agreement expires May 11, 2014. The board of directors is now commencing a search for a new CEO.
Chembio Diagnostics Reports Second Quarter 2013 Financial Results
GlobeNewswire - Thu Aug 08, 7:50AM CDT
Chembio Diagnostics, Inc.(Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious diseases, today reported financial results for the three months and six months ended June 30, 2013.
Alere Beats, Earnings Up 40.5% - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 07, 11:15AM CDT
Net revenues went up 9.1% to $764.0 million in the second quarter of 2013, exceeding the Zacks Consensus Estimate of $722 million
(0)
(0)Chembio Diagnostics (CEMI) Stock Research Links
Scroll down for more posts ▼